[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523988":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":38,"responsibleParty":56,"collaborators":60,"id":65,"slug":12,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":12,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":12,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":12,"overallStatus":40,"whyStopped":12,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"control group","NO_INTERVENTION","Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg\u002F day or mirena +GnRHa 3.75mg subcutaneous injection monthly);",null,{"label":14,"type":15,"description":16,"interventionNames":17},"experimental group","EXPERIMENTAL","Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg\u002F day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg\u002F day; Or rosuvastatin 5mg\u002F day; Or pivastatin 2mg\u002F day);",[18],"Drug: statins (oral atorvastatin calcium tablet 20mg\u002F day; Or rosuvastatin 5mg\u002F day; Or pivastatin 2mg\u002F day);",[20],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":12},"DRUG","statins (oral atorvastatin calcium tablet 20mg\u002F day; Or rosuvastatin 5mg\u002F day; Or pivastatin 2mg\u002F day);",[14],[25],{"name":26,"affiliation":27,"role":28},"Jianliu Wang, professor","Peking University \u002FPeking University People's Hospital","STUDY_DIRECTOR",[30,34],{"name":26,"role":31,"phone":32,"phoneExt":12,"email":33},"CONTACT","00861088324381","wangjianliu1203@163.com",{"name":35,"role":31,"phone":36,"phoneExt":12,"email":37},"HE YIJIAO, PHD\u002FMD","18301512017","heyijiao2017@pku.edu.cn",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Beijing","Beijing Municipality","100044","China",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52,54],{"name":53,"role":31,"phone":33,"phoneExt":12,"email":33},"Jianliu Wang",{"name":35,"role":55,"phone":12,"phoneExt":12,"email":12},"SUB_INVESTIGATOR",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Wang Jianliu","Secretary of the Party Committee,Vice president",[61,63],{"name":62,"class":6},"Beihang University",{"name":64,"class":6},"Peking University","100523988",false,"NCT06102863","Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","Inclusion Criteria:\n\n* The pathological types are consistent with:\n\n  1. Atypical endometrial hyperplasia;\n  2. Patients with highly differentiated endometrioid adenocarcinoma, stage IA, and pelvic and abdominal MRI before treatment excluded deep muscle infiltration, cervical involvement, and extrauterine metastasis;\n  3. There is a strong need to preserve reproductive function; Age ≤45 years old;\n  4. Progesterone resistant patients predicted by the progesterone sensitivity prediction model (NCT05647109) established by our team in the previous study of endometrial cancer were prospectively randomized; The predicted progesterone sensitive patients were prospectively observed;\n  5. Informed consent and signed informed consent;\n  6. have follow-up conditions and are willing to continue to follow the visitors in the hospital;\n  7. Patients with normal\u002Fabnormal blood lipids who have not taken any lipid-lowering drugs;\n  8. A. Newly treated patients: did not use any nursery therapy drugs (progesterone, GNRH-a); B. 1 course of treatment (12 weeks) the lesions persisted; C. Partial remission for 2 courses of treatment (24 weeks);\n\nExclusion Criteria:\n\n* (1) Patients with severe internal diseases and severe impairment of liver and kidney function;\n\n  (2) Disease progression, extrauterine metastasis (cervical invasion or distant metastasis such as pelvic cavity) during treatment;\n\n  (3) People with therapeutic drug allergies and contraindications;\n\n  (4) Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; Patients with breast cancer or other hormone-dependent tumors that cannot use progesterone;\n\n  (5) Patients with deep vein thrombosis, stroke and myocardial infarction during treatment;\n\n  (6) Alcoholics (\\> 20g\u002F day);\n\n  (7) Smokers (\\> 15 cigarettes\u002Fday)","FEMALE","17 Years","45 Years",{"count":74,"type":75},38,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.",[81],"Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","2025-04-25",{"date":84,"type":85},"2025-04-29","ACTUAL",{"date":87,"type":85},"2023-04-01",{"date":89,"type":75},"2025-09-01",{"name":5,"class":6},1]